A Simple Study Where Every Patient Knows That They Are Taking Wiesbaden 30C Homeopathic Medicine For Checking If It Will Help With Androgenetic Alopecia Which Have Symptoms Include Hair Thinning, Hair Fall And Pattern Baldness (Mild To Moderate) In Adults 18 50 Years Old.

An Open-Label Prospective Pilot Study to Evaluate the Role of Wiesbaden 30C in Mild to Moderate Androgenetic Alopecia (Age 18 50 Years) Using Basic and Specific (BASP) Classification - nil

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/102062

Enrollment

Registered

2026-01-27

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L648- Other androgenic alopecia

Interventions

Intervention1: Wiesbaden 30C: The Case Taking Of The Patient Will Be Done As Per Case Performa And With The Symptom Similarity Of Wiesbaden 3oc Will Be Prescribe To The Patient Of Male Pattern And Fem

Eligibility

Inclusion criteria

Inclusion criteria: Clinically Diagnosed Mild To Moderate Androgenetic Alopecia (Basic And Specific Classification): Males M0 To M2 And C0 To C2, Females F1 To F3 And V1 To V2) Willingness To Give Written Informed Consent

Exclusion criteria

Exclusion criteria: Severe Androgenetic Alopecia, Scarring Alopecia, Alopecia Areata, Telogen Effluvium. History Of Scalp Surgery, Hair Transplantation, Or Invasive Interventions For Androgenetic Alopecia. Cases With Severe Androgenetic Alopecia Unlikely To Respond To Non Surgical Treatment According To Basic And Specific Classification Pattern M3 And C3 And U1/2/3 Of Basic Types And V3 Of Specific Type. Patients With Traumatic Scalp Injury Or Significant Scalp Infections In The Past 6 Months. Patients Currently Receiving Or In Past 3 Month Systemic Treatments For Aga (Example Finasteride, Dutasteride) Or Undergoing Scalp-Specific Therapies (Example Low-Level Laser Therapy, Platelet-Rich Plasma). Patients With Severe Comorbidities Such As Uncontrolled Diabetes, Thyroid, Autoimmune, Advanced Cardiovascular Diseases, And Renal/Hepatic Failure. Pregnant Women And Lactation

Design outcomes

Primary

Measure	Time frame
To Evaluate The Role Of Wiesbaden 30c In Improving Hair Growth In Patients With Androgenetic Alopecia.Timepoint: 6 Months	—

Secondary

Measure	Time frame
To Evaluate Change In Basic And Specific Grade In Patient With Androgenetic AlopeciaTimepoint: 6 Months	—

Countries

India

Contacts

Public ContactKRUNAL RAJESH BRAHMBHATT

PARUL INSTITUTE OF HOMOEOPATHY AND RESEARCH

santosh.hudgikar28869@paruluniversity.ac.in9663875835

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026